These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8701822)

  • 1. Renal cell carcinoma (RCC). Place of chemotherapy either alone or in combination regimens.
    Focan C
    Acta Urol Belg; 1996 May; 64(2):9-10. PubMed ID: 8701822
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kotake T; Kinouchi T
    Prog Clin Biol Res; 1989; 303():661-9. PubMed ID: 2780667
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of embolization/chemoembolization in the treatment of renal cell carcinoma.
    Kato T; Sato K; Abe R; Moriyama M
    Prog Clin Biol Res; 1989; 303():697-705. PubMed ID: 2506558
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
    Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bowel perforation after radiotherapy in a patient receiving sorafenib.
    Peters NA; Richel DJ; Verhoeff JJ; Stalpers LJ
    J Clin Oncol; 2008 May; 26(14):2405-6. PubMed ID: 18467733
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant therapy of renal carcinoma].
    Novák J; Stolz J; Dvorácek J
    Cas Lek Cesk; 2002 Sep; 141(18):578-80. PubMed ID: 12422568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality of life in patients with renal carcinoma].
    Vukotić-Maletić V; Stojković-Djordjević B; Hadzi-Djokić J; Dragićević D
    Acta Chir Iugosl; 1999; 46(1 Suppl):15-8. PubMed ID: 10951771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination embolization and radiofrequency ablation therapy for renal cell carcinoma in the setting of coexisting arterial disease.
    Mondshine RT; Owens S; Mondschein JI; Cizman B; Stavropoulos SW; Clark TW
    J Vasc Interv Radiol; 2008 Apr; 19(4):616-20. PubMed ID: 18375310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.
    Figlin RA
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):662-5. PubMed ID: 20040906
    [No Abstract]   [Full Text] [Related]  

  • 15. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent or metastatic renal cell carcinoma.
    Shah RN; Ahmad T; Eisen TG
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
    Ishii T; Marumo K
    Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy.
    Li J; Wang G; Chu Y; Rong R; Zhu T
    Med Hypotheses; 2008 Oct; 71(4):527-9. PubMed ID: 18687532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genitourinary malignancies.
    Smith MR; Kantoff P
    Cancer Chemother Biol Response Modif; 1999; 18():394-417. PubMed ID: 10800495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.